SCHEMBL30139872

SCHEMBL30139872

CCc1cccc(-c2cc3n(n2)CCC3)n1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.45
TGFBR1 P36897 1/20 0.45
MAPK14 Q16539 1/20 0.45
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100200 0.81 GRM5 (0.54) THRBTGFBR1MAPK14GRM5
SCHEMBL29832119 0.81 GRM5 (0.54) THRBTGFBR1MAPK14GRM5
SCHEMBL13455921 0.75
SCHEMBL244011 0.73 CCR1 (0.46) THRBTGFBR1MAPK14
SCHEMBL19732370 0.72 TGFB1 (0.39) GRM5
SCHEMBL14108198 0.72 GRM5 (0.54) GRM5
SCHEMBL6104496 0.71
SCHEMBL2522518 0.69 GRM5 (0.51) GRM5
SCHEMBL16297439 0.68 TGFBR1 (0.63) THRBTGFBR1MAPK14
SCHEMBL2525007 0.67 THRB (0.43) THRBTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049159-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2026-02-19 US disclosed
US-12473377-B2 Antibody-ALK5 inhibitor conjugates and their uses SYNTHIS THERAPEUTICS, INC. (US) 2025-11-18 US disclosed
US-11987558-B1 ALK5 inhibitors and their uses SYNTHIS THERAPEUTICS, INC. (US) 2024-05-21 US disclosed
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2023-05-04 US disclosed
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses SYNTHIS THERAPEUTICS, INC. (US) 2023-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473377-B2 Antibody-ALK5 inhibitor conjugates and their uses ALK, ALKBH5, ALKBH3 THRB 1981/4885TGFBR1 528/4885MAPK14 2643/4885
US-11987558-B1 ALK5 inhibitors and their uses ALK, ALKBH3, ALKBH5 THRB 892/4885TGFBR1 106/4885MAPK14 1923/4885
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses ALK, ALKBH5, ALKBH3 THRB 1981/4885TGFBR1 528/4885MAPK14 2643/4885
US-20260049159-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, CD2, TGFBR2 THRB 63/4885TGFBR1 5/4885MAPK14 1007/4885
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 THRB 1981/4885TGFBR1 528/4885MAPK14 2643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.